VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Panobinostat plus ruxolitinib in myelofibrosis

Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares some findings from a study evaluating the use of panobinostat plus ruxolitinib in patients with myelofibrosis (MF) and comments on the growing role of combination therapies in the field. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter